The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.
Hussain M., Fung S., Libbrecht E., Sablon E., Cursaro C., Andreone P., et al. (2006). Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. JOURNAL OF CLINICAL MICROBIOLOGY, 44, 1094-1097 [10.1128/JCM.44.3.1094-1097.2006].
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
ANDREONE, PIETRO;
2006
Abstract
The INNO-LiPA HBV DR v2 assay is designed to detect hepatitis B virus mutations conveying resistance to lamivudine and adefovir. Our study confirms that this assay can simultaneously detect the presence of lamivudine and adefovir resistance mutations in clinical samples, has a high degree of concordance with sequencing, and can detect mutants earlier.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
